Sam­sung Bi­o­log­ics pro­motes new CEO from with­in to head next phase of rapid man­u­fac­tur­ing ex­pan­sion

Rid­ing a wave of red-hot in­vest­ments in bi­o­log­ics, Sam­sung Bi­o­log­ics — the bio­phar­ma CD­MO arm of the South Ko­re­an tech gi­ant — is string­ing to­geth­er a se­ries of ma­jor down pay­ments on man­u­fac­tur­ing. Now, the firm has found the right leader to steer it in­to its next phase, and it didn’t have to look far.

Sam­sung Bi­o­log­ics has cho­sen John Rim, a three-year ex­ec­u­tive VP, to be its next pres­i­dent and CEO, cit­ing his con­tri­bu­tions in rapid­ly ex­pand­ing the CD­MO’s man­u­fac­tur­ing ca­pac­i­ties since he joined the com­pa­ny in 2018.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER